4e2a5058-c190-49de-97f4-0ba7be7ebfe8
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 78
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.600
- E2F_TARGETS+0.510
- OXIDATIVE_PHOSPHORYLATION+0.490
- MYC_TARGETS_V2+0.480
- PROTEIN_SECRETION+0.460
- MTORC1_SIGNALING+0.390
- UNFOLDED_PROTEIN_RESPONSE+0.390
- DNA_REPAIR+0.340
- G2M_CHECKPOINT+0.340
- PEROXISOME+0.310
Top 10 suppressed
- IL6_JAK_STAT3_SIGNALING-0.470
- INTERFERON_GAMMA_RESPONSE-0.420
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.400
- INFLAMMATORY_RESPONSE-0.380
- APICAL_SURFACE-0.370
- HEDGEHOG_SIGNALING-0.370
- ALLOGRAFT_REJECTION-0.350
- MYOGENESIS-0.350
- COAGULATION-0.340
- IL2_STAT5_SIGNALING-0.340
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ULC0410T_S45 | — | cohortA4 | 0.938 |
| 2 | TCGA-C8-A1HN-01A-11R-A137-07 | — | B | 0.927 |
| 3 | c6e243ee-b2d9-408e-ac05-ccbcffa805ab | — | — | 0.919 |
| 4 | TCGA-AR-A0TY-01A-12R-A115-07 | — | B | 0.917 |
| 5 | 45a758dc-af09-48d3-8cd2-15232593f385 | — | — | 0.915 |
| 6 | e332b15a-f2dc-4282-9f33-2c87dea834b1 | — | — | 0.912 |
| 7 | TCGA-A8-A06Q-01A-11R-A034-07 | — | C | 0.912 |
| 8 | SRR8518448 | — | C | 0.912 |
| 9 | TCGA-AN-A0AK-01A-21R-A00Z-07 | — | C | 0.909 |
| 10 | BS_G23JJAZY | Supratentorial Ependymoma | — | 0.906 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.600 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.510 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.490 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.480 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.460 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.390 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.390 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.340 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.340 | Inavolisib | — uncovered |
| PEROXISOME | 0.310 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.250 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.250 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.140 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.120 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.110 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.110 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.110 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.020 | Inavolisib | — uncovered |